Responder analysis to demonstrate the effect of targeting type 2 inflammatory mechanisms with dupilumab across objective and patient-reported endpoints for patients with severe chronic rhinosinusitis with nasal polyps in the SINUS-24 and SINUS-52 studies

Affiliations

• ¹ Ghent University, Ghent, Belgium.
• ² Karolinska Institutet, Stockholm, Sweden.
• ³ The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
• ⁴ Allergy-Immunology Division and the Sinus and Allergy Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
• ⁵ Personalized Medicine, Asthma & Allergy - Humanitas Clinical and Research Center IRCCS, Rozzano, Milan, Italy.
• ⁶ Department of Biomedical Science, Humanitas University, Milan, Italy.
• ⁷ Eastern Virginia Medical School, Norfolk, Virginia, USA.
• ⁸ Department of Otorhinolaryngology, Charité-Universitätsmedizin Berlin, Berlin, Germany.
• ⁹ Section of Rhinology and Allergy, Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Marburg, Philipps-Universität Marburg, Marburg, Germany.
• ¹⁰ Sanofi, Cambridge, Massachusetts, USA.
• ¹¹ Sanofi, Reading, UK.
• ¹² Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.
• ¹³ Sanofi, Bridgewater, New Jersey, USA.